Skip to main content
. 2020 Nov 30;29:100652. doi: 10.1016/j.eclinm.2020.100652

Table 1.

Total and therapy-stratified male-to-female ratios of included studies.

Studies (n) Sex-specific analysis (n) Patients (n) Female (%) Male-to-female ratio (range)
I. TOTAL 30 1 6156 41 1•4 (0•7–7•0)
treatment group 23 . 3292 40 1•5 (0•8–5•0)
control group 23 . 2757 43 1•3 (0•5–7•0)
II. THERAPY GROUPS
II.I ANTIVIRAL AGENTS
Viral entry and replication inhibitors
Remdesivir 2 1 1299 37 1•7 (1•5–1•8)
treatment group 2 . 699 36 1•7 (1•3–1•9)
control group 2 . 600 36 1•8 (1•7–1•9)
Lopinavir/ritonavir 5 0 460 47 1•1 (0•7–1•5)
treatment group 5 . 247 46 1•2 (0•8–1•6)
control group 5 . 196 47 1•1 (0•5–1•4)
Favipiravir 1 0 236 53 0•9 (-)
treatment group 1 . 116 49 1•0 (-)
control group 1 . 120 58 0•7 (-)
Umifenovir 1 0 81 44 1•3 (-)
treatment group 1 . 45 38 1•6 (-)
control group 1 . 36 53 0•9 (-)
II.II ANTIMALARIA AGENT
(hydroxy)chloroquine 8 0 3325 41 1•4 (0•7–2•7)
treatment group 8 . 1814 40 1•5 (0•8–3•4)
control group 8 . 1511 43 1•3 (0•6–2•1)
II.III IMMUNE MODULATORS
Convalescent plasma 6 0 75 39 1•6 (1•0–7•0)
case series 5 . 54 44 1•3 (0•8–7•0)
observational study 1 . 21 24 3•2 (-)
treatment group 1 . 6 17 5•0 (-)
control group 1 . 15 27 2•8 (-)
IL-6 pathway inhibitors 3 0 147 27 2•7 (2•3–6•0)
treatment group 1 . 42 21 3•7 (-)
control group 1 . 69 36 1•8 (-)
IL-1 pathway inhibitors 1 0 45 16 5•4 (-)
treatment group 1 . 29 17 4•8 (-)
control group 1 . 16 13 7•0 (-)
Corticosteroids 3 0 488 47 1•1 (1•0–1•8)
treatment group 3 . 294 46 1•2 (1•1–2•7)
control group 3 . 194 49 1•0 (0•9–1•5)

Data are presented as numbers and percentages.